ENGN

The past six months have seen significant volatility and a substantial decline in enGene Therapeutics Inc.'s stock price, trending down by 75.25% from November 2025 to May 2026. In November 2025, the company reported updated preliminary data from the LEGEND pivotal cohort, showing a 63% complete response (CR) rate at any time and a 62% CR rate at 6 months for patients enrolled under an amended protocol. In December 2025, enGene reported full-year 2025 financial results, reiterating the promising preliminary LEGEND data and a cash runway into the second half of 2028. In April 2026, the company changed its name from enGene Holdings Inc. to enGene Therapeutics Inc. In May 2026, enGene announced updated interim results from the Phase 2 LEGEND pivotal cohort, showing a 54% complete response rate at any time, with weaker-than-expected durability. Following the May 2026 data release, the stock experienced a sharp decline, leading to multiple analyst downgrades and an investigation by a shareholder-rights law firm.